81895-1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: November 8, 2002
Express Scripts, Inc.
--------------------------------------------------------------------------------
(Exact Name of Registrant as specified in its Charter)
Delaware 0-20199 43-1420563
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission File No.) (I.R.S. Employer
of corporation) Identification No.)
13900 Riverport Drive, Maryland Heights, Missouri 63043
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (314) 770-1666
-----------------------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 9. Regulation FD Disclosure
As previously disclosed, on August 6, 2002 Express Scripts, Inc.(the
"Company") received a subpoena duces tecum issued by the Defense Criminal
Investigative Service (DCIS) of the Office of Inspector General of the
Department of Defense. This subpoena sought information pertaining to the
purchase of Lipitor, a cholesterol-reducing drug, from Parke-Davis,
Incorporated, Warner Lambert Company and Pfizer, Inc. for sale to the TRICARE
program, a Department of Defense health care program. The Company has recently
been advised by DCIS that it is no longer necessary for the Company to respond
to this subpoena.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EXPRESS SCRIPTS, INC.
Date: November 8, 2002 By: /s/ Barrett A. Toan
_______________________________
Barrett A. Toan
Chairman and Chief Executive Officer